Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467689 | 1.00 | STING1 (0.37) | STING1DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL19532914 | 1.00 | STING1 (0.37) | STING1DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL29467625 | 1.00 | STING1 (0.37) | STING1DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL12592808 | 1.00 | STING1 (0.37) | STING1DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL1781057 | 1.00 | STING1 (0.37) | STING1DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL916562 | 1.00 | STING1 (0.37) | STING1DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL24668232 | 1.00 | STING1 (0.37) | STING1DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL917272 | 1.00 | STING1 (0.37) | STING1DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL21877221 | 1.00 | STING1 (0.37) | STING1DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL5737163 | 0.92 | STING1 (0.37) | STING1DGAT1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2626368-B1 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LTD (IN) | 2016-12-21 | — | — | EP | disclosed |
| EP-2626368-B1 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LTD (IN) | 2016-12-21 | — | — | EP | disclosed |
| US-9102758-B2 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9101596-B2 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9102758-B2 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9101596-B2 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9101596-B2 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9102758-B2 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| EP-1773878-B1 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | BIOCON LTD (IN) | 2015-03-04 | — | — | EP | disclosed |
| EP-1773878-B1 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | BIOCON LTD (IN) | 2015-03-04 | — | — | EP | disclosed |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | RADHAKRISHNAN BALASINGAM | 2010-04-29 | — | — | US | disclosed |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | RADHAKRISHNAN BALASINGAM | 2010-04-29 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| EP-1773878-A2 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | Nobex Corporation (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014673-A2 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | NOBEX CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060018874-A1 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060019874-A1 | Cation complexes of insulin compund conjugates, formulation and uses thereof | NOBEX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-20060019873-A1 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019873-A1 | Cation complexes of insulin compound conjugates, formulations and uses thereof | GPR119, INSR, IAPP | STING1 4575/4885DGAT1 1210/4885HDAC3 414/4885 |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | FABP2, SLC27A1, SLC27A2 | STING1 2607/4885DGAT1 146/4885HDAC3 1818/4885 |
| US-20060018874-A1 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | FABP2, SLC27A1, SLC27A2 | STING1 2672/4885DGAT1 142/4885HDAC3 1797/4885 |
| US-20060019874-A1 | Cation complexes of insulin compund conjugates, formulation and uses thereof | INSR, GPR119, IAPP | STING1 3621/4885DGAT1 280/4885HDAC3 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.